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SUMMARY
The contribution of the different waves and sites of developmental hematopoiesis to fetal and adult 
blood production remains unclear. Here, we identify lymphatic vessel endothelial hyaluronan 
receptor-1 (LYVE1) as a marker of yolk sac (YS) endothelium and definitive hematopoietic stem 
and progenitor cells (HSPCs). Endothelium in mid-gestation YS and vitelline vessels, but not the 
dorsal aorta and placenta, were labeled by Lyve1-Cre. Most YSHSPCs and erythro-myeloid 
progenitors were Lyve1-Cre lineage traced, but primitive erythroid cells were not, suggesting that 
they represent distinct lineages. Fetal liver (FL) and adult HSPCs showed 35%–40% Lyve1-Cre 
marking. Analysis of circulation-deficient Ncx1−/− concepti identified the YS as a major source of 
Lyve1-Cre labeled HSPCs. FL proerythroblast marking was extensive at embryonic day (E) 11.5–
13.5, but decreased to hematopoietic stem cell (HSC) levels by E16.5, suggesting that HSCs from 
multiple sources became responsible for erythropoiesis. Lyve1-Cre thus marks the divergence 
between YS primitive and definitive hematopoiesis and provides a tool for targeting YS definitive 
hematopoiesis and FL colonization.
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In Brief
Lee et al. identify LYVE1 as a marker that is highly enriched in yolk sac endothelium and 
definitive HSPCs during mid-gestation. Lyve1-Cre-labeled hematopoietic cells initiate fetal liver 
erythropoiesis and give rise to more than one-third of fetal and adult HSCs. The primitive 
erythroid lineage develops from LYVE1 negative precursors.
INTRODUCTION
Developmental hematopoiesis is composed of temporally orchestrated programs that 
generate both the differentiated blood cells to support embryonic growth and the 
undifferentiated hematopoietic stem cells (HSCs) to sustain post-natal hematopoiesis. This 
challenge is met by segregating hematopoiesis into multiple waves that occur in different 
anatomical locations. The earliest (“primitive”) hematopoietic wave starts in the extra-
embryonic yolk sac (YS) at embryonic day (E) 7.5 and gives rise to erythroid cells that 
fulfill the immediate metabolic needs of the embryo (EM) (Moore and Metcalf, 1970). They 
are characterized by the expression of embryonic β globin (betaH1 in mice) (Haar and 
Ackerman, 1971). At E8.5–9.5, the YS also generates an intermediate (“transient-
definitive”) wave of erythro-myeloid progenitors (EMPs) (McGrath et al., 2015; Mikkola 
and Orkin, 2006; Palis et al., 1999) that produce red cells expressing “definitive” adult type 
β globins (beta-major in mice) (McGrath et al., 2003). However, YS EMPs lack self-renewal 
ability and lymphoid potential, the hallmarks of HSCs. It has been proposed that EMPs 
initiate fetal liver (FL) definitive hematopoiesis and play roles in supporting embryonic 
survival (Chen et al., 2011), inflammatory signaling during HSC emergence (Es-pín-Palazón 
et al., 2014), and adult tissue-resident macrophage development (Gomez Perdiguero et al., 
2015). However, the duration and significance of this intermediate hematopoietic wave are 
not fully understood.
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The final (“definitive”) wave generates self-renewing, multipotent HSCs that sustain lifelong 
production of all blood cell types. Transplantable HSCs are first identified at E10.5–11.5 in 
the intra-embryonic para-aortic splanchnopleural/aorta-gonad-mesonephros region (pSP/
AGM) and the vitelline and umbilical vessels that connect the pSP/AGM to extra-embryonic 
tissues (Medvinsky and Dzierzak, 1996; Müller et al., 1994). Several studies suggest that the 
YS and the placenta (PL) can also generate multipotent hematopoietic stem and progenitor 
cells (HSPCs) de novo (Inlay et al., 2014; Rhodes et al., 2008; Samokhvalov et al., 2007; 
Weissman et al., 1977, 1978; Zeigler et al., 2006). Observations from direct transplantation 
of pre-circulation YS into congenic embryos and inducible Runx1 lineage-tracing studies 
supported the hypothesis that YS contributes to adult hematopoiesis (Samokhvalov et al., 
2007; Weissman et al., 1977, 1978). Furthermore, in vitro experiments with placental tissues 
isolated before or without the onset of blood circulation demonstrated multi-lineage 
hematopoietic potential (Rhodes et al., 2008; Zeigler et al., 2006). However, the degree to 
which each organ contributes to the post-natal HSC pool is unknown.
Lineage tracing and time-lapsed imaging of HSPC emergence in vitro and in vivo evidenced 
that definitive HSPCs arise from specialized endothelial cells, named hemogenic 
endothelium (Bertrand et al., 2010; Boisset et al., 2010; Chen et al., 2009; Eilken et al., 
2009; Lancrin et al., 2009; Zovein et al., 2008). Hemogenic competence in the endothelium 
is established by the stem cell leukemia gene/T cell acute leukemia gene 1 (Scl/Tal1), which 
activates a broad transcriptional network of hematopoietic regulators and prevents 
misspecification of the endothelium to cardiac fate (Van Handel et al., 2012). SCL activates 
RUNX1 and other transcription factors that enable HSPC emergence from hemogenic 
endothelium (Org et al., 2015). SCL is also essential for the generation of primitive erythroid 
cells and controls the terminal maturation of erythroid cells at all stages of ontogeny 
(Mikkola et al., 2003a; Schlaeger et al., 2005; Shivdasani et al., 1995). The identity of the 
precursors for the primitive erythroid cells and the timing when they diverge from the 
definitive hematopoietic lineages are not known. The presumption that primitive and 
definitive hematopoietic waves represent distinct lineages that arise from their own 
precursors (“lineage switch” model) has been challenged by studies that show sequential 
expression of both the primitive and definitive globins (“maturational switch” model) during 
erythroid maturation (Kingsley et al., 2006; McGrath et al., 2011; Palis, 2008;Qiu et al., 
2008).
Although the fundamentals of the developmental hematopoietic hierarchy are gradually 
being revealed, the contributions of each wave and hemogenic tissue to fetal and post-natal 
hematopoiesis remain poorly defined because of the lack of wave- and tissue-specific tools 
that would enable prospective isolation and tracking of the progeny of the temporally and 
spatially overlapping blood precursors. Most surface antigens expressed in the hemogenic 
endothelium or emerging HSPCs–e.g., Flk1, CD31, VE-Cadherin, Tie2, CD41, ckit, and 
Sca1–are developmentally regulated but not specific to any individual wave or anatomical 
site (McKinney-Freeman et al., 2009; Mikkola and Orkin, 2006). The use of inducible 
lineage-tracing studies using regulatory elements of hematopoietic transcription factors (e.g., 
Runx1) is complicated by the fact that the expression of such factors is not restricted to a 
particular hemogenic tissue (Samokhvalov et al., 2007). Thus, there are no robust methods to 
separate or genetically target in vivo individual hematopoietic waves or hemogenic tissues.
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Here, we identify the lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) as a 
marker that is differentially and highly expressed in YS endothelium during HSPC 
development. Lineage tracing by reporter gene expression and conditional deletion of the 
hematopoietic regulators Scl and Runx1 by Lyve1-Cre distinguished YS endothelium, 
EMPs, and definitive HSPCs from the primitive erythroid lineage. Our data suggest that 
Lyve1-Cre-labeled cells primarily originate from the YS and/or vitelline vessels and 
contribute to 35%–40% of fetal and adult HSC compartments. At E11.5, the FL pro-
erythroblast pool is dominated by LYVE1-lineage cells, whereas by late gestation, the level 
of marking is similar to the HSC compartment, implying a temporal switch in the 
composition of precursors responsible for FL erythropoiesis. Lyve1-Cre thus provides a 
unique tool to investigate the contribution of YS hemogenic endothelium to fetal and adult 
hematopoiesis and the factors that regulate the fate of these cells.
RESULTS
LYVE1 Protein Is Expressed in YS Endothelium and Definitive Hematopoietic Cells
To define the precursors and respective contributions of the different waves to fetal and adult 
hematopoiesis, we sought for cell surface markers expressed in hemogenic endothelium that 
are tissue or wave specific. From a list of genes encoding surface proteins highly expressed 
in YS endothelium (Van Handel et al., 2012), Lyve1 emerged as a promising candidate. 
Initially reported as a marker for lymphatic vessels, LYVE1 expression was later 
documented also in mid-gestation YS vasculature, FL sinusoids, intersomitic vessels, and 
the cardinal vein, while being minimal in the dorsal aorta (DA) (Banerji et al., 1999; Gordon 
et al., 2008).
Because LYVE1 expression has not been assessed in the context of developmental 
hematopoiesis, LYVE1 protein expression was surveyed in hemogenic organs by 
immunostaining and flow cytometry (FACS). Immunofluorescence (IF) at E10.5 
demonstrated robust LYVE1 protein expression in YS and vitelline vasculature, whereas no 
signal was observed in the PL, umbilical vessels, and DA (Figure 1A). As reported 
previously, LYVE1 was also expressed in the cardinal vein at E10.5. At E9.5, LYVE1 
protein expression in CD31+ endothelial cells was ubiquitous in the YS, but minimal in the 
EM and PL (Figures 1B and 1C). Scant LYVE1 protein was discernible in PL vasculature 
during HSPC emergence (E11.5) and expansion/maturation (E13.5); however, some LYVE1 
protein could be detected at late gestation (E16.5) when the PL HSC pool has already 
diminished (Gekas et al., 2005) (Figure S1A). At E13.5, LYVE1 expression was also 
abundant in FL sinusoids and the azygous vein – tissues incapable of de novo HSPC 
generation–but not the aorta (Figure S1B).
Analysis of the early concepti revealed LYVE1 expression in Tie2+CD31+ angioblasts 
already by E7.5 (Figure S1C). At E8.5, LYVE1 was present in YS Tie2+CD31+ angioblasts, 
but excluded from Ter119+ primitive erythroid cells (Figure S1C), the embryo, and allantois 
(data not shown). These data identify the YS and the vitelline vessels as the primary sites 
harboring LYVE1-expressing endothelium during HSPC emergence. Moreover, these data 
imply that LYVE1 protein is already expressed in the YS at the time when primitive 
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hematopoiesis begins and the endothelium that gives rise to YS definitive lineages is 
specified.
We next assessed the expression of LYVE1 protein in YS hematopoietic cells. IF and FACS 
analyses showed that Ter119+ primitive erythroid cells were devoid of LYVE1 expression 
(Figures 1D, 1E, and 1I). In contrast, LYVE1 expression was observed in 47.0% ± 19.1% 
SD of E9.25–9.5 YS CD41midcKit+Ter119− HSPC population (Figures 1F, 1G, and 1I), 
which consists predominantly of EMPs (Ferkowicz et al., 2003; Mikkola et al., 2003b). Co-
staining for the EMP marker CD16/32 (McGrath et al., 2015) suggested that most LYVE1+ 
HSPCs in E9.25 YS are EMPs (Figure 1G). In contrast to YS HSPCs and EMPs, the E13.5 
FL LSK (Lin−Sca1+cKit+) CD150+ HSC subset showed minimal LYVE1 expression 
(Figures 1H and 1I).
To assess the origin of LYVE1+ HSPCs, LYVE1 expression was examined in concepti that 
were devoid of blood circulation due to a defective sodium calcium exchanger (Ncx1) 
required for cardiac activity (Koushik et al., 2001). FACS analysis of Ncx1−/− tissues 
showed that LYVE1 expression was robust in CD41midcKit+ HSPCs in the YS, but minimal 
in the PL or EM (Figures 1J and 1K). Comparable results were observed with 
CD16/32+CD41midcKit+ EMPs (Figure S1D). These data suggest that the YS is the primary 
source of LYVE1+-expressing HSPCs, including EMPs, in mid-gestation concepti.
Lyve1-Cre Labels YS Endothelium and Vitelline Vessels
To define the contribution of LYVE1+ candidate hemogenic endothelial cells to fetal and 
adult hematopoiesis, lineage tracing was performed by breeding Lyve1-eGFP-hCre knockin 
mice (Pham et al., 2010) (referred as “Lyve1-Cre” hereafter) with reporter mouse lines. As 
originally reported, endogenous eGFP signal from the Lyve1-Cre line was weak and did not 
interfere with the signal from the reporter GFP. We first used RosamT/mG fluorescent 
reporter mice (Figure 2A), in which all cells of the conceptus initially express tdTomato. 
Upon activation of Cre re-combinase, the floxed membrane-targeted tdTomato cassette is 
excised, allowing the expression of the downstream membrane-targeted EGFP in Cre-
expressing cells and their progeny (Muzumdar et al., 2007). Maternal blood cells in the PL 
could be separated from the cells of the conceptus because they were devoid of any 
fluorescence.
Analysis of Lyve1-Cre;RosamT/mG concepti by fluorescence microscopy demonstrated 
Lyve1-Cre labeling already in E8.5 YS (Figure 2B). By E10.5, marking was apparent in YS 
and vitelline vessels as well as the FL (Figures 2Ci, 2Ciii, and 2Civ), but absent from 
umbilical and placental large vessels (Figure 2Cii). In contrast to the robust labeling of 
CD31+ YS and vitelline vessels, the dorsal aorta showed minimal Lyve1-Cre labeling 
(Figures 2C and 2D).
FACS analysis of hemogenic tissues from Lyve1-Cre; RosamT/mG concepti at E9.5–E11.5 
further documented that VE-Cad+CD31+ endothelial cells were GFP labeled abundantly in 
the YS but minimally in the PL and EM (the latter includes the caudal half at E9.5 and the 
aorta-gonad-mesonephros region at later ages) (Figures 2E and 2F). These data raised the 
hypothesis that Lyve1-Cre labels YS hemogenic endothelium.
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Lyve1-Cre Lineage Traces YS Definitive HSPCs but Bypasses the Primitive Erythroid 
Lineage
We next interrogated the contribution of LYVE1 lineage cells to the different hematopoietic 
compartments. Lyve1-Cre was crossed with a R26-stop-YFP strain, where deletion of the 
transcriptional stop preceding the YFP sequence in the Rosa26 locus leads to marking of all 
progenies with YFP (Figure 3A) (Friedrich and Soriano, 1991).
FACS analysis of E8.5 Lyve1-Cre;YFP YS showed labeling in one-third of angioblasts, 
whereas none of the Ter119+ primitive erythroid cells were marked (Figure 3B). Likewise, 
no labeling was observed in Ter119+ cells in E9.0 Lyve1-Cre;YFP YS, although 90% of 
erythroid cells were labeled when the YFP reporter strain was crossed with Tie2/Tek-Cre 
mouse, in which Cre is activated in hemato-vascular precursors after gastrulation (Figure 
3C) (Kisanuki et al., 2001). 100% labeling was observed with the germ-cell-specific Vasa-
Cre mouse, in which Cre is active during fertilization, enabling Cre recombination in all 
cells of the conceptus (data not shown) (Gallardo et al., 2007). Hence, using two different 
Cre lines, we verified that the absence of YFP signal in Lyve1-Cre;YFP E9.0 primitive 
erythroid cells was not explained by silencing of the Rosa26 locus. Later in development, 
however, Lyve1-Cre tracing of primitive erythroid cells could not be tracked because 
reporter expression from the Rosa26 locus was silenced as the primitive erythroid cells 
matured, irrespective of the Cre line used (data not shown).
Lack of Lyve1-Cre labeling in primitive erythroid cells was confirmed by analyzing E9.5 
Lyve1-Cre;RosamT/mG concepti. Although many CD43+ hematopoietic cells in YS had 
switched from tdTomato to GFP expression, CD71+Ter119+ primitive erythroid cells 
retained tdTomato expression (Figure S2A), documenting absent Lyve1-Cre marking, 
despite intact activity of the Rosa26 locus. These data confirm that the primitive erythroid 
lineage does not originate from LYVE1-expressing hemogenic endothelium.
In contrast to the unlabeled primitive erythroid cells, 69.7% ± 14.8% SD of CD41midcKit+ 
HSPCs in E9.5 Lyve1-Cre;YFP YS was marked by YFP (Figures 3D and 3G). These data 
imply that Lyve1-Cre marks the stage when the precursors generating YS definitive 
hemogenic endothelium and HSPCs have separated from the primitive erythroid lineage.
Lyve1-Cre Labels a Subset of Fetal and Adult HSCs
To investigate whether Lyve1-Cre marking is restricted to EMPs or includes HSCs, we 
assessed the contribution of lineage-traced cells to fetal and adult HSCs. At E13.5, when the 
FL HSC compartment has become established and is rapidly expanding, 38.9% ± 11.6% SD 
of the LSK CD150+ HSCs were YFP marked (Figures 3E and 3G). In the adult, comparable 
fractions of YFP labeling were found among LSK CD150+ HSCs (37.4% ± 11.1% SD) and 
Mac1+Gr1+ myeloid cells (38.2% ± 6.0% SD) in the bone marrow (BM) and CD4+CD8+ T 
lymphocytes (39.4% ± 3.5% SD) in the thymus (Figures 3F and 3G). The uniform degree of 
post-natal Lyve1-Cre marking in all major lineages is in stark contrast to the absent or low 
expression of LYVE1 protein in HSCs or in cells committed to the different hematopoietic 
lineages (Figure S2B). These data establish that more than one-third of long-term 
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repopulating HSCs derive from the Lyve1-Cre lineage, and that they were labeled during 
embryonic development.
YS Is the Primary Source of Lyve1-Cre Lineage-Derived HSPCs at Mid-gestation
Although the YS was the only hemogenic organ that showed extensive Lyve1-Cre labeling 
of endothelium during HSPC emergence (Figure 2F), the PL (Figures 3H and 3I) and EM 
(data not shown) also harbored CD41midcKit+ HSPCs with reporter expression. To examine 
how circulating cells contribute to the HSPC census in each hemogenic organ, YFP 
fluorescence was examined in blood cells of heartbeat-deficient Ncx1−/− concepti. Although 
the YS maintained the richly labeled HSPC pool (79% ± 2.8% SD), the absence of 
circulation in Ncx1−/− mutants depleted YFP+ labeled HSPCs from the PL (Figures 3H and 
3I). The CD16/32+ EMP subset in Ncx1−/− mutants also showed a similar redistribution of 
YFP+ fractions (Figure S2C). These data suggested that the YS is the main source of Lyve1-
Cre-line-age-traced HSPCs and EMPs at mid-gestation. Due to the severely defective 
generation of HSPCs in the Ncx1−/− mutant embryos, labeling of HSPCs generated in this 
organ could not be reliably assessed.
To target the hematopoietic cells derived from the LYVE1 lineage, Lyve1-Cre was used to 
delete the Runt-related transcription factor 1 (Runx1) gene, which is required for the 
generation of EMPs and HSCs. Comparison of Lyve1-Cre;Runx1fl/− concepti to control 
tissues at E9.5 showed near depletion of CD41midckit+ HSPCs in the conditional knockout 
YS. Both the PL and EM showed a partial reduction in their HSPC populations, likely 
reflecting the lack of migration of Lyve1-Cre-depleted HSPCs from the YS. The HSPC 
populations observed in the PL and EM likely represent the HSPCs generated in situ, which 
were unaffected by Lyve1-Cre mediated Runx1 deletion (Figure 3J). A parallel defect in 
myelo-erythroid colony formation was evident in Lyve1-Cre;Runx1fl/− YS (Figure 3K). As 
expected from the known function of Runx1 in hemogenic endothelium (Chen et al., 2009), 
genotyping of YS colonies confirmed that only rare cells that had escaped Lyve1-Cre-
mediated Runx1 deletion formed colonies (Figure 3L). These genetic labeling and gene 
ablation data verified that YS HSPCs are efficiently targeted by Lyve1-Cre, whereas the PL 
and EM harbor native HSPCs that do not originate from the LYVE1 lineage.
Lyve1-Cre Lineage Tracing Identifies a Temporal Switch in the Precursors Responsible for 
FL Erythropoiesis
To investigate the contribution of Lyve1-Cre lineage cells to FL hematopoiesis, we assessed 
the fraction of lineage-traced cells in different hematopoietic populations from mid to late 
gestation. Lyve1-Cre marking in the FL Lin−cKit+CD34+Sca1+ HSC compartment peaked at 
E11.5 (61.3% ± 17.8% SD), when the FL seeding by HSCs begins, and leveled to 36.4% 
± 11.7% SD at E13.5 and 41.4% ± 10.4% SD at E16.5 (Figures 4A and 4D). Of note, 
CD150, the Slam family marker associated with long-term reconstituting HSCs in mice 
(Kiel et al., 2005) was not used in E11.5 FL because it is not reliably expressed in HSCs 
during early FL colonization (McKinney-Freeman et al., 2009). However, incorporating 
CD150 expression to further characterize HSCs at E13.5 did not change their fraction of 
Lyve1-Cre marking (data not shown). These data suggest that LYVE1-lineage cells are 
major contributors to initially colonize the FL HSC compartment, whereas by E13.5, non-
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lineage-traced HSCs co-seed the FL. The uniform degree of HSC marking from E13.5 to 
adult implies that the respective contributions of Lyve1-Cre labeled and non-labeled HSCs to 
the HSC pool remains stable after the FL HSC compartment has been established by E13.5.
In addition to serving as a site for HSC expansion, the FL supports definitive erythropoiesis 
through most of the fetal life. Whereas the primitive erythroid cells differentiate in the YS 
and undergo maturation in circulation, the progenitors for definitive erythroid cells must 
transit through the FL to differentiate and enucleate (McGrath et al., 2011). It has been 
proposed that the precursors that first colonize the FL and initiate definitive erythropoiesis 
derive from the YS, but their origin and the duration of their contribution have not been 
experimentally proven.
FACS analysis of Lyve1-Cre;YFP FL at E11.5 revealed that it contained CD71+Ter119− pro-
erythroblasts (ProE) and ckit+ CD34− hematopoietic progenitor cells (HPCs) with extensive 
YFP marking (76.7% ± 4.7% SD and 79.3% ± 3.0% SD, respectively) (Figures 4A and 4D), 
which was comparable to the level measured in E9.5 YS CD41midcKit+ HSPCs (Figures 3D 
and 3G). This suggests that the YS supplies the precursors that first colonize the FL to 
initiate definitive erythropoiesis. By E13.5, 63.2% ± 8.7% SD of the ProE and 51.0% 
± 5.5% SD of FL HPCs derived from the LYVE1 lineage (Figures 4B and 4D). These 
compartments displayed significantly higher marking than the Lin−Sca1+cKit+CD34+ HSC 
subset (36.4% ± 11.7% SD), implicating that the progenitors responsible for FL-definitive 
erythropoiesis derive from a different source than most HSCs at this stage. By E16.5, the 
ProE- and HSC-enriched populations exhibited similar degrees of Lyve1-Cre marking 
(41.2% ± 8.1% SD and 41.4% ± 10.3% SD, respectively), suggesting that by late gestation, 
HSCs become responsible for FL erythropoiesis (Figures 4C and 4D).
Lyve1-Cre-Mediated Deletion of Scl/Tal1 Targets Early FL Definitive Erythropoiesis but 
Spares the Primitive Erythroid Lineage
To confirm that the Lyve1-Cre strain can be used to manipulate early definitive 
erythropoiesis without affecting primitive erythropoiesis, we created a Lyve1-Cre-mediated 
conditional knockout of the transcription factor SCL. Although SCL is essential for the 
specification of hemogenic endothelium (Porcher et al., 1996; Van Handel et al., 2012), it is 
dispensable for HSC maintenance (Mikkola et al., 2003a) because of redundancy with LYL1 
(Souroullas et al., 2009). Because SCL is required for the terminal differentiation of all 
erythroid cells, inactivation of Scl by Tie2-Cre results in defects in both primitive and 
definitive erythropoiesis (Schlaeger et al., 2005). As previously reported, May-Grunwald 
Giemsa stain of E12.5 peripheral blood from Tie2-Cre;Sclfl/− mutants displayed abnormal 
primitive erythroid cells that were mitotic, binucleated, or had a larger nucleus-to-cytoplasm 
ratio than control littermates, implying defective maturation (Figure 5A). Furthermore, 2-hr 
5-Bromo-2’-deoxyuridine (BrDU) pulse analysis showed a high fraction of mutant erythroid 
cells undergoing DNA replication (Figure 5B). In contrast, when Scl was excised in Lyve1-
Cre-expressing cells, the primitive erythroid cells did not show abnormal morphology or 
proliferation, indicating that they had been spared from Scl inactivation (Figures 5A and 
5B).
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Both Tie2-Cre;Sclfl/− and Lyve1-Cre;Sclfl/− E12.5 fetal livers showed an increase in the 
CD71+Ter119− ProE fraction (Figures 5C and 5E), consistent with delayed maturation 
reported in Scl-deficient definitive erythroid cells (Mikkola et al., 2003a; Schlaeger et al., 
2005). This defect was ameliorated by E13.5 (Figures 5D and 5E), likely due to 
replenishment of the FL ProE pool by a new source of unaffected precursors. These data 
verify that Lyve1-Cre deletes Scl specifically from the transient-definitive, but not primitive 
erythroid cells, enabling studies that address the impact of the different erythroid waves on 
embryonic development.
DISCUSSION
The challenge of tracking the origin and contribution of the different waves of 
developmental hematopoiesis in vivo has limited the understanding of their unique roles in 
the embryo and adult. We report that LYVE1 expression and lineage tracing can be used to 
specifically examine the definitive hematopoiesis originating from the YS and/or vitelline 
vessels without targeting the primitive erythroid lineage or the majority of the HSC 
compartment generated elsewhere in the conceptus.
LYVE1 protein expression and Lyve1-Cre fate mapping distinguished endothelial cells from 
the YS and vitelline vessels from those from other hemogenic organs at the developmental 
window when HSPCs emerge. Although LYVE1+ EMPs and HSPCs could be detected in all 
hemogenic organs in concepti with normal circulation, analysis of heartbeat-deficient 
Ncx1−/− concepti implied that the YS is the main source of LYVE1+ HSPC and EMPs. 
These data propose that some, if not all, HSCs of Lyve1-Cre lineage, which constitute more 
than one-third of the fetal and the adult HSC pools, originate from the YS and/or vitelline 
vessels. However, because LYVE1 protein expression appears in PL vasculature at late 
gestation and a low level of Lyve1-Cre marking is noted in PL and EM endothelium at mid-
gestation, our data do not exclude the possibility that other hemogenic organs may also 
contribute to the LYVE1-lineage-traced HSC pool. The Ncx1−/− model cannot be used to 
assess adult-repo-pulating HSC activity of Lyve1-Cre-marked cells because these embryos 
die by E10.0–before transplantable HSCs can be har-vested–and because heartbeat is critical 
for proper HSC development (North et al., 2009). Hence, the question of whether all or most 
of the 35%−40% Lyve1-Cre-marked fetal and adult HSPCs arise from the YS and/or 
vitelline vessels requires further studies using different experimental systems. Nevertheless, 
because the YS generates predominantly Lyve1-Cre-marked HSPCs, while the PL and the 
EM produce mostly unmarked ones, our data propose that HSCs from multiple anatomical 
sites contribute to adult hematopoiesis. How these different lineages of HSCs contribute to 
the various hematopoietic subsets in the adult can now be approached experimentally in vivo 
using the Lyve1-Cre model. This is important because HSCs are heterogeneous and can 
show cell intrinsic biases to different hematopoietic lineages in an age-dependent manner 
(Beerman et al., 2010; Benz et al., 2012; Pang et al., 2011; Sieburg et al., 2006; Yamamoto 
et al., 2013).
Our data document that the LYVE1+ endothelium in the YS does not give rise to primitive 
erythroid cells. The absence of LYVE1 protein expression and marking in the primitive 
erythroid cell contrasts with the abundant protein expression and marking in YS definitive 
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HSPC. These data imply that these two hematopoietic lineages have separated from a 
common mesodermal precursor before Lyve1-Cre becomes active. The YS thus gives rise to 
at least two lineages of erythroid cells that originate from distinct precursors. The Lyve1-Cre 
lineage trace may thus provide clarity to studies that challenged the “lineage switch model” 
by reporting that the types of globins expressed in primitive or definitive erythroid lineages 
are not mutually exclusive because the cells undergo “maturational globin switch” during 
erythroid differentiation (Kingsley et al., 2006; McGrath et al., 2011; Palis, 2008; Qiu et al., 
2008).
LYVE1 expression and lineage tracing offer a powerful tool to separate primitive erythroid 
lineage from early fetal definitive erythropoiesis. The defects in both primitive and definitive 
erythroid cell differentiation caused by the conditional deletion of Scl by Tie2-Cre 
(Schlaeger et al., 2005) were uncoupled using Lyve1-Cre, which disrupted only the early FL 
definitive erythropoiesis. Selective inactivation of key hematopoietic regulators in Lyve1-Cre 
progenies makes it possible to study the requirement of such factors in early FL 
erythropoiesis without the confounding effects of early embryonic lethality, as in Scl null 
embryos (Porcher et al., 1996; Shivdasani et al., 1995), or primitive erythroid defects, as in 
Tie2-Cre;Sclfl/− concepti.
The Lyve1-Cre model also provides in vivo evidence that the earliest progenitors seeding 
and initiating FL erythropoiesis are products of a distinct lineage that likely emerges from 
the YS. However, the deletion of Scl in LYVE1-lineage cells causes only a temporary effect 
on FL erythropoiesis, possibly because progenitors from other sources that were spared from 
Lyve1-Cre deletion also converge to the FL and replenish the initially attenuated erythroid 
compartment. Future studies will inform whether the erythroid progenitors or HSCs 
belonging to the LYVE1 lineage exhibit different properties than those arising from non-
LYVE1-lineage precursors.
LYVE1 is expressed abundantly in lymphatic vessels and lymph node sinus endothelial 
cells, but its expression has also been described in other cell types, such as liver blood 
sinusoids and tissue macrophages (Mouta Carreira et al., 2001; Pham et al., 2010; 
Schledzewski et al., 2006). In the YS, LYVE1 expression is not related to lymphatic identity 
because the YS does not contain lymphatic vasculature (Banerji et al., 1999; Gordon et al., 
2008). It is unknown how the YS- and vitelline-vessel-restricted expression pattern of 
LYVE1 among hemogenic vessels is established, and whether this is intrinsically regulated 
or if it involves signals from the microenvironment. It will be interesting to determine 
whether LYVE1 expression is also enriched in YS and vitelline vessels and HSPCs during 
human development, and how the expression pattern is preserved during ESC differentiation.
The functional significance of LYVE1 expression in YS endothelial or hematopoietic cells is 
unknown. Although it was suggested to serve in cell adhesion/transmigration and as a 
scavenger for hyaluronan turnover, mouse knockout studies in either 129/C57BL/6 or 
C57BL/6 background were unable to demonstrate a critical function for LYVE1 in these 
processes or in embryonic development in general (Gale et al., 2007). The Cre cassette was 
inserted into the 3′UTR of the endogenous Lyve1 locus, avoiding disruption in the LYVE1 
protein. Hence, our model cannot be used to answer whether loss of LYVE1 causes subtle 
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effects in hematopoiesis that would be observed upon more detailed examination or 
backcrossing to other genetic backgrounds. However, because of the hematopoietic wave- 
and tissue-restricted expression of LYVE1, the Lyve1-Cre model can be exploited to uncover 
new functions for the different blood progenitor lineages and HSC sources during 
developmental and adult hematopoiesis.
EXPERIMENTAL PROCEDURES
Mouse Models
Lyve1-eGFP-hCre knockin mice (C57BL/6) (Pham et al., 2010) were crossed with two 
reporter lines: (1) R26-YFP carrying a floxed transcriptional stop upstream of the YFP in 
Rosa26 locus (Srinivas et al., 2001), and (2) double-fluorescent reporter (RosamT/mG), where 
cells express Tomato constitutively but switch to GFP upon excision (Muzumdar et al., 
2007). Whereas YFP or GFP fluorescence rendered from crossing with the reporter lines 
could clearly highlight the Cre-excised cells, eGFP from Lyve1-eGFP-hCre alone could not 
be discerned by fluorescence microscopy, as previously reported (Pham et al., 2010). FACS 
analysis confirmed the low eGFP signal from Lyve1-eGFP-hCre, which did not overlap with 
the intense YFP or GFP signal. Hence, for simplicity, the Lyve1-eGFP-hCre is referred as 
Lyve1-Cre. To label the entire hemato-vascular compartment, Tie-2/Tek-Cre mice (Kisanuki 
et al., 2001) were bred with the R26-YFP line. To label all cells of the conceptus, the germ-
cell-specific Vasa-Cre was crossed with the R26-YFP line. Lyve1-Cre;YFP mice were 
further crossed with Ncx1+/− mice (Koushik et al., 2001) to generate Ncx1−/− mutants that 
underwent Lyve1-Cre labeling and lacked circulation. Although some contaminating 
embryonic red blood cells (RBCs) could occasionally be found in the embryo proper of 
Ncx1−/− concepti, only embryos with less than 5% RBC contamination were used in the 
analysis. Lyve1-Cre was also bred with Runx1fl/− (Growney et al., 2005; Wang et al., 1996) 
and Sclfl/− (Mikkola et al., 2003a; Shivdasani et al., 1995). Embryos were not separated 
based on sex, and both female and male embryos were studied. Mice were maintained 
according to protocols of Animal Research Committee at the University of California, Los 
Angeles, and the University of California, Irvine, who approved these studies.
See the Supplemental Experimental Procedures for preparation of tissue sections, 
immunostaining, flow cytometry, clonogenic progenitor assay, cytospin, cell proliferation 
assay, and statistical analysis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• LYVE1 is expressed in yolk sac endothelium and hematopoietic stem and 
progenitor cells
• Lyve1-Cre marks yolk sac definitive hematopoiesis but bypasses primitive 
erythropoiesis
• LYVE1 lineage cells initiate fetal liver definitive erythropoiesis
• A subset of fetal and adult hematopoietic stem cells are derived from the 
LYVE1 lineage
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Figure 1. LYVE1 Protein Is Expressed in Yolk Sac Endothelium and Hematopoietic Stem and 
Progenitor Cells
(A) LYVE1 protein is detected by IF in E10.5 YS, vitelline vessels (VVs), and the cardinal 
vein (CV), but is absent from the PL, umbilical vessels (UVs), and DA. Representative 
images from three independent experiments. Scale bar, 100 μm.
(B) IF staining shows co-localization of LYVE1 in E9.5 YS CD31+ endothelium. 
Representative image from three independent experiments. Scale bar, 100 μm.
(C) FACS analysis of CD31+CD41−Ter119− endothelium in YS, PL, and caudal half of the 
EM of one representative E9.5 conceptus. Corresponding histograms of LYVE1+ endothelial 
cells show robust LYVE1 expression in YS endothelium only. Data from n = 11 from three 
independent experiments are represented as mean ± SD; ***P ≤ 0.001.
(D) LYVE1 protein is not discernible by IF in Ter119+ primitive erythroid cells in E10.5 YS. 
Representative image from two independent experiments is shown. Scale bar, 50 μm.
Lee et al. Page 17
Cell Rep. Author manuscript; available in PMC 2020 January 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(E) Representative FACS plots indicate that Ter119+ primitive erythroid cells (pRBCs) do 
not express LYVE1 in E9.5 YS or E11.0 peripheral blood (PB).
(F) IF staining of E9.5 YS shows co-expression of LYVE1 protein with HSPC marker 
CD41. Representative image from three independent experiments is shown. Scale bar, 50 
μm.
(G) Representative FACS plots show LYVE1 expression in CD41midcKit+Ter119− HSPCs 
and its subset, CD16/32+ EMPs in E9.25 YS.
(H) Representative FACS plots of E13.5 FL document minimal LYVE1 expression in Lin
−Sca1+cKit+ CD150+ HSC compartment.
(I) LYVE1 expression is prominent in mid-gestation YS HSPCs and EMPs. Data from n = 8, 
three independent experiments for YS pRBC; n = 28,10 independent experiments for YS 
HSPC; n = 8, three independent experiments for YS EMP; and n = 6, two independent 
experiments for FL HSC subset are shown as mean ± SD.
(J) Representative FACS plots of hemogenic tissues in Ncx1−/− E9.5 concepti demonstrate 
the enrichment of LYVE1-expressing CD41midcKit+Ter119− HSPCs in the YS.
(K) Significantly higher HSPC fraction in the YS than in the PL or EM expresses LYVE1 
protein in Ncx1−/− concepti. Quantification of n = 23 for control and n = 11 for Ncx1−/− 
from five independent experiments is represented as mean ± SD. p values refer to the 
difference between LYVE1+ fractions; ****P ≤ 0.0001.
See also Figure S1 and Table S1.
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Figure 2. Lyve1-Cre Labels Yolk Sac Endothelium and Vitelline Vessels
(A) Schematic of mouse model for tracing Lyve1-Cre lineage cells using the RosamT/mG 
reporter line.
(B) Brightfield and whole mount fluorescence microscopy images of Lyve1-Cre;mTmG 
E8.5 concepti show the replacement of Tomato (red) by GFP (green) expression in the YS. 
Representative image from n = 8 concepti from two independent experiments. Scale bar, 500 
μm.
(C) Brightfield and whole mount fluorescence microscopy images of YS, EM, and PL at 
E10.5. (i) shows GFP expression in the fetal liver (FL; dashed outline) and the vitelline 
vessels (VV; green arrow). (ii) shows intact Tomato activity in PL and umbilical vessels 
(UV; red arrow) and in the dorsal aorta (DA). GFP+ hematopoietic cells (green arrowheads) 
are found in PL vasculature (ii), heart (H) and limb bud (LB; dashed outline) (iii), and YS 
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(iv). GFP expression is prominent throughout YS vasculature (iv). Representative image of n 
= 18 embryos from three independent experiments. Scale bar, 500 μm.
(D) At E10.5, GFP labeling is widespread in YS and VV CD31+ endothelium, but minimal 
in the DA. Representative image from two independent experiments. Scale bar, 250 μm.
(E) Representative FACS plots of GFP labeling of VE-Cad+CD31+ endothelial cells in E9.5 
YS, PL, and caudal half of the EM.
(F) Bar graphs of endothelial cells show robust Lyve1-Cre lineage tracing in YS at E9.5–
E11.5. EM refers to the caudal half of the embryo at E9.5 and the aorta-gonad-mesonephros 
region at E10.5 and E11.5. Data are from pools of embryos from three (E9.5), seven (E10.5), 
and three (E11.5) independent experiments and are represented as mean ± SD.
See also Table S1.
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Figure 3. Lyve1-Cre Targets Yolk-Sac-Definitive Hematopoiesis
(A) Schematic of mouse model for tracing Lyve1-Cre-marked cells using the R26-stop-YFP 
reporter.
(B) Representative FACS plots of E8.5 conceptus show Lyve1-Cre;YFP labeling in 
Tie2+CD31+ angioblasts, but not in Ter119+ primitive erythroid cells (pRBCs).
(C) Representative FACS plots of E9.0 YS demonstrate labeling of Ter119+ pRBC by Tie2-
Cre, but not by Lyve1-Cre.
(D) Representative FACS plots of E9.5 YS demonstrate labeling of YS CD41midcKit
+Ter119− HSPCs and CD16/32+ EMPs by Lyve1-Cre.
(E and F) Representative FACS plots display similar YFP marking in the Lin−Sca1+cKit
+CD150+ HSC of E13.5 FL (E) and 8-month-old adult BM (F).
(G) Quantification shows a contrast of YFP marking between pRBCs (n = 4, two 
independent experiments) and YS HSPCs (n = 15, 7 independent experiments). Lyve1-Cre 
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marking in E13.5 FL Lin−Sca1+cKit+CD150+ HSCs (n = 15, 4 independent experiments) is 
similar to 8-month-old adult BM HSCs, BM Mac1+Gr1+ myeloid cells (n = 8, two 
independent experiments), and thymus CD4+CD8+ T lymphocytes (n = 7, two experiments). 
No comparison of marking between populations yielded statistical difference. Data are 
represented as mean ± SD.
(H) Representative FACS plots of E9.5 Lyve1-Cre;YFP Ncx1−/− concepti show preservation 
of YFP+ HSPCs in the YS but near depletion in the PL when blood circulation is absent.
(I) Quantification of YFP+ fraction in HSPCs of E9.5 Ncx1−/− concepti with impaired 
circulation. Data from n = 16 for Ncx1CTR and n = 5 for Ncx1−/− from three independent 
experiments are represented as mean ± SD; **p value of the difference in YFP+ fractions at 
≤ 0.01.
(J) Representative FACS plots and quantification of HSPCs in hemogenic organs of E9.5 
LYve1-Cre;Runx1fl/− tissues show depletion of HSPCs from the YS upon conditional 
deletion of Runx1 in LYVE1 lineage cells. The loss in HSPCs is partial in the PL and 
insignificant in the EM. Data from n = 4 for mutants and n = 9 for controls from three 
independent experiments are represented as mean ± SD. p values are shown as ns if > 0.05; 
*P ≤ 0.05; **P ≤ 0.01.
(K) Quantification of myelo-erythroid colonies per embryo equivalent (ee) from each organ. 
Data from n = 4 for mutants and n = 3 for controls from two independent experiments are 
represented as mean ± SD.
(L) Genotyping of Runx1 alleles in representative colonies.
See also Figure S2 and Table S1.
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Figure 4. Progenitors of Lyve1-Cre Lineage Initiate Fetal Liver Hematopoiesis
(A) Representative FACS plots of Lyve1-Cre marking in hematopoietic subpopulations in 
one representative E11.5 FL: Ter119− CD71+ proerythroblasts (ProEs), Ter119−cKit+ HPCs, 
and Ter119−CD34+cKit+Sca1+ HSPCs.
(B) Representative FACS plots of FL subsets at E13.5.
(C) Representative FACS plots of FL subsets at E16.5.
(D) Comparative analysis of E11.5, E13.5, and E16.5 FL illustrates a shift in hematopoietic 
populations derived from the Lyve1-Cre lineage. Data from n = 9, three independent 
experiments for E11.5, n = 18, three independent experiments for E13.5, and n = 13, two 
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independent experiments for E16.5, are represented as mean ± SD. p values are shown as ns 
if > 0.05; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
See also Table S1.
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Figure 5. Lyve1-Cre Targets Early Fetal Liver Definitive Hematopoiesis
(A) May-Grunwald Giemsa stain of E12.5 peripheral blood (PB) shows primitive erythroid 
defects in Tie2-Cre;Sclfl/− blood cells (arrows), but not in Lyve1-Cre;Sclfl/− blood. 
Representative images from three independent experiments are shown.
(B) Representative FACS plots of BrDU staining of E12.5 PB illustrate excessive 
proliferative activity in Tie2-Cre;Sclfl/− primitive erythroid cells, but not in Lyve1-Cre;Sclfl/− 
cells. Bar graphs from n = 22 controls and n = 4 knockouts from three independent Tie2-
Cre;Sclfl/− experiments and n = 6 controls and n = 3 knockouts from two independent 
Lyve1-Cre;Sclfl/− experiments are shown as mean ± SD.
(C) E12.5 FLs from both Tie2-Cre;Sclfl/− (upper panel) and Lyve1-Cre;Sclfl/− (lower panel) 
embryos exhibit accumulation of proerythroblasts (ProEs).
Lee et al. Page 25
Cell Rep. Author manuscript; available in PMC 2020 January 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(D) At E13.5, the defect in ProE fraction in Lyve1-Cre;Sclfl/− FL has corrected.
(E) Quantification of ProE fractions in E12.5 and E13.5 FL. Data from n = 2 (E12.5 Tie2-
Cre;Sclfl/−) and n = 6 (control), n = 3 (E12.5 Lyve1-Cre;Sclfl/−) and n = 7 (control), and n = 
4 (E13.5 Lyve1-Cre; Sclfl/−) and n = 14 (control) from two independent experiments for 
each genotype and age are shown as mean ± SD.
See also Table S1.
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